Glycemic Screening in Childhood May Predict Diabetes-Related Complications, According to New Data
ADA 2023: Findings from a new study show that higher levels of glycemia in childhood are associated with future microvascular complications, such as nephropathy and retinopathy.
New Data Suggest Higher Doses of Oral Semaglutide Beneficial for Management of Type 2 Diabetes
ADA 2023. Results from PIONEER PLUS trial showed oral semaglutide 25 mg and 50 mg were superior than 14 mg in reducing HbA1c and body weight in adults with T2D.
Triple Agonist Retatrutide Associated with Weight Loss of up to 24% in 48-Week Phase 2 Trial
ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.
Oral Semaglutide 50 mg May be Effective Option for Obesity Treatment, According to OASIS 1 Study Authors
ADA 2023. Once-daily oral semaglutide 50 mg induced 15.1% weight loss in adults with overweight or obesity without type 2 diabetes vs placebo.
Oral GLP-1 Agonist Orforglipron Leads to ~15% Mean Body Weight Reduction in Adults with Overweight/Obesity
ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.
SURMOUNT-2: Tirzepatide Treatment Leads to Average 15% Weight Loss in Adults with T2D, Obesity
ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.
“Triagonist” Therapy for Type 2 Diabetes and Comorbidities to be Previewed at 2023 ADA Scientific Sessions
ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.
Flash CGM Increases Time in Range for T2D Patients on Noninsulin Therapies Not at Goal HbA1c
ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.
Continuous Glucose Monitoring Linked to Better Glycemic Control, Reduced Hospitalizations in Study of Veterans Health Administration Data
ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.
Glycemic Variability with Tirzepatide Significantly Lower vs Degludec as Assessed by CGM
ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.
Poorly Controlled T2D Improves with Initiation of rtCGM in Primary Care
ADA 2022: Primary care patients with T2D and HbA1c >7.5% achieved as much as a 1.5% drop in HbA1c after initiating real time continuous glucose monitoring.
Study: AI-powered Intervention Led to Highest Reported Rate of T2D Remission to Date
ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.
Semaglutide 2.4 mg Reduces 10-year Risk of Type 2 Diabetes in Patients with Overweight, Obesity
ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.
Dulaglutide Improves HbA1c for Youth with Type 2 Diabetes without Change in BMI
ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.
Oral Semaglutide in Real-world Study Found Highly Effective for Uncontrolled HbA1c
ADA 2022: Oral semaglutide may be particularly effective for T2D patients with HbA1c ≥9% and prescribed more frequently for these patients by primary care clinicians.
Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.
Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor Agonists
ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.
Younger Age and Higher HbA1c Among Factors Linked to CGM Uptake in New Study
ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.
Patients with Diabetes Up to 4-times More Likely to Develop Long COVID-19
ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.
Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial
ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.
Tirzepatide Slows Renal Decline in T2D Patients with CKD in First Analysis of Dual Agent on Kidney Function
ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.
At ADA 2021, John Buse, MD, PhD, says US Must Focus on Control of Obesity, Other T2D Risk Factors
Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.
Inside GRADE: Exec Committee Member John Buse, MD, PhD, Toplines Study Results, Calls for More Head-to-Head Research
Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.
ADA 2021: Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D
ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.
GLP-1 RA, Insulin More Effective Second-line vs Sulfonylurea, DPP-4 Inhibitor for T2D
Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.
ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD
ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.
ADA 2021: Renoprotection with Finerenone Consistent Regardless of SGLT2 Inhibitor Use
ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.
ADA 2021: Study Finds Hospitalization Rates for New-onset Pediatric T2D Doubled During Pandemic
Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.
ADA 2021 Symposia Focus on Health Disparities Exposed and Deepened by COVID-19 Pandemic
Leading international diabetes researchers and clinicians will use the ADA's 81st annual Scientific Sessions as an ideal classroom to examine pandemic impact on diverse populations with diabetes.
ADA Virtual Meeting Will Offer 5 Symposia on Latest COVID-19 Findings
The upcoming ADA virtual 81st Scientific Sessions will feature 5 sessions on the latest diabetes developments learned during the initial phases of the COVID-19 pandemic.
2 Clarke Drive Cranbury, NJ 08512